Pfizer Targets Apotex In Fight To Block Generic Lyrica
Pfizer claims Toronto-based Apotex, Canada's largest pharmaceutical company, has infringed two patents with its plans to manufacture an alternative to Lyrica, which is available in capsule and oral solution form. Pfizer “will be substantially and irreparably harmed if Apotex is not enjoined from infringing,” the suit said.
A representative for Apotex did not immediately return...
To view the full article, register now.